文献速递精神分裂症与精神病性障碍

精神分裂症治疗抵抗与白质区域易损性指数研究

White Matter in Schizophrenia Treatment Resistance.
PubMed 文献 · Am J Psychiatry · 2019-07-29

本研究纳入122例精神分裂症患者(包括治疗起始、治疗响应和治疗抵抗者)及78名健康对照,测试白质区域易损性指数(RVI)作为治疗抵抗和认知缺陷的预测因子。结果显示治疗抵抗症状患者的白质RVI最高(均值0.38),显著高于治疗响应患者(均值0.30),且RVI与处理速度和阴性症状显著相关。结论提示白质区域缺陷易感性增加治疗抵抗可能性。

要点

  • 治疗抵抗患者白质RVI最高,显著高于治疗响应患者。
  • 治疗起始时患者RVI显著高于健康对照。
  • RVI与处理速度和阴性症状显著相关。

核心结论

  • 精神分裂症以特定区域模式影响白质微结构,白质区域缺陷易感性增加治疗抵抗可能性。
  • 克服精神分裂症治疗抵抗的研发应考虑将白质作为重要靶点。

研究设计与样本

  • 研究样本N=122,平均年龄38.2岁,包括治疗起始患者N=45、治疗响应患者N=40、治疗抵抗患者N=37,以及健康对照N=78(平均年龄39.2岁)。
  • 测试白质区域易损性指数(RVI)作为治疗抵抗和认知缺陷的预测因子。

主要发现

  • 治疗抵抗症状患者白质RVI均值0.38(SD=0.2),显著高于治疗响应症状患者均值0.30(SD=0.02)。
  • 治疗起始时精神分裂症患者RVI均值0.18(SD=0.03),健康对照均值0.13(SD=0.02),患者显著高于对照。
  • RVI与处理速度表现和阴性症状显著相关。

临床怎么用

  • 白质RVI可能作为精神分裂症治疗抵抗风险的预测指标。
  • 针对治疗抵抗的干预策略可考虑白质微结构作为靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Failure of antipsychotic medications to resolve symptoms in patients with schizophrenia creates a clinical challenge that is known as treatment resistance. The causes of treatment resistance are unknown, but it is associated with earlier age at onset and more severe cognitive deficits. The authors tested the hypothesis that white matter deficits that are involved in both neurodevelopment and severity of cognitive deficits in schizophrenia are associated with a higher risk of treatment resistance. METHODS: The study sample (N=122; mean age, 38.2 years) included schizophrenia patients at treatment initiation (N=45), patients whose symptoms were treatment responsive (N=40), and patients whose symptoms were treatment resistant (N=37), as well as healthy control subjects (N=78; mean age, 39.2 years). White matter regional vulnerability index (RVI) was tested as a predictor of treatment resistance and cognitive deficits. Higher RVI is indicative of better agreement between diffusion tensor imaging fractional anisotropy across the brain in an individual and the pattern identified by the largest-to-date meta-analysis of white matter deficits in schizophrenia. RESULTS: Patients with treatment-resistant symptoms showed the highest white matter RVI (mean=0.38 [SD=0.2]), which was significantly higher than the RVI among patients with treatment-responsive symptoms (mean=0.30 [SD=0.02]). At the onset of treatment, schizophrenia patients showed significantly higher RVI than healthy control subjects (mean=0.18 [SD=0.03] and mean=0.13 [SD=0.02], respectively). RVIs were significantly correlated with performance on processing speed and negative symptoms. CONCLUSIONS: Schizophrenia affects white matter microstructure in specific regional patterns. Susceptibility to white matter regional deficits is associated with an increased likelihood of treatment resistance. Developments to overcome schizophrenia treatment resistance should consider white matter as an important target.

来源:Am J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Kochunov P, Huang J, Chen S, et al. White Matter in Schizophrenia Treatment Resistance. Am J Psychiatry. 2019. PMID: 31352812. doi:10.1176/appi.ajp.2019.18101212

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。